Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Non-DEHP and Phthalate-Free Tubing Now Available for Routine Laboratory Applications

By BiotechDaily International staff writers
Posted on 27 Aug 2013
A major European manufacturer of high-performance flexible tubing and other plastic laboratory products has introduced a bio-based, phthalate-free product for use in routine laboratory applications.

Saint-Gobain Performance Plastics (Paris, France) the manufacturer of Tygon high-performance flexible tubing, has recently introduced a bio-based, phthalate-free product. DEHP Di(2-ethylhexyl phthalate), a common plasticizer, has been removed from existing Tygon formulations.

The next-generation DEHP- and phthalate-free Tygon S3 tubing is made with a bio-based plasticizer and the product’s new sustainable formulations are biodegradable and deliver superior pump life. For example, Tygon S3 E-3603 non-DEHP tubing was specially formulated for resistance to flex-fatigue and abrasion. In many peristaltic pump applications, it outlasts the original R-3603 by a factor of three to one. As tubing for an instrumentation connection, vent, drain and other general laboratory applications, Tygon S3 E-3603 Tubing offers superior life, which minimizes the labor and expense of replacement.

New Tygon S3 formulations include Tygon S3 E-3603 General Laboratory Tubing and Tygon S3 E-LFL Long Flexible Life Tubing. Tygon R-1000 has also been replaced by Tygon E-1000, soft and flexible non-DEHP tubing.

“The change to non-DEHP tubing is integral to the company’s continued efforts toward safety, compliance, and sustainability,” said Katia May, laboratory market manager for Saint-Gobain Performance Plastics. “Saint-Gobain is the first manufacturer to remove DEHP and phthalates from tubing products for laboratory applications and beyond. We are committed to providing superior, smart, safe, and sustainable flexible tubing with unsurpassed performance.”

Related Links:

Saint-Gobain


Channels

Genomics/Proteomics

view channel
Image: The bone marrow of mice with normal ether lipid production (top) contains more white blood cells than are found in the bone marrow of mice with ether lipid deficiency (bottom) (Photo courtesy of Washington University School of Medicine).

Inactivating Fatty Acid Synthase Reduces Inflammation by Interfering with Neutrophil Membrane Function

The enzyme fatty acid synthase (FAS) was shown to regulate inflammation by sustaining neutrophil viability through modulation of membrane phospholipid composition. Neutrophils are the most abundant... Read more

Drug Discovery

view channel
Image: Researchers have attached two drugs—TRAIL and Dox—onto graphene strips. TRAIL is most effective when delivered to the external membrane of a cancer cell, while Dox is most effective when delivered to the nucleus, so the researchers designed the system to deliver the drugs sequentially, with each drug hitting a cancer cell where it will do the most damage (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Anticancer Drug Delivery System Utilizes Graphene Strip Transporters

The ongoing search by cancer researchers for targeted drug delivery systems has generated a novel approach that uses graphene strips to transport simultaneously the anticancer agents TRAIL (tumor necrosis... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Biotech Acquisition Designed to Accelerate the Development and Marketing of Immunosequencing Applications

Adaptive Biotechnologies Corp. (Seattle, WA, USA), a developer of next-generation sequencing (NGS) to profile T-cell and B-cell receptors, has acquired of Sequenta, Inc. (South San Francisco, CA, USA), which is expected to expedite and expand the use of innovative immunosequencing technology for researchers and clinicians... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.